SPRO - Spero Therapeutics, Inc.

0.5998
0.018   2.968%

Share volume: 239,359
Last Updated: 04-07-2025
Pharmaceutical Products/Pharmaceutical Preparations: 0.00%

PREVIOUS CLOSE
CHG
CHG%
$0.58
0.02
0.03%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
13%
Profitability 8%
Dept financing 14%
Liquidity 50%
Performance 10%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-3.88%
1 Month
-20.24%
3 Months
-40.02%
6 Months
-51.63%
1 Year
-64.30%
2 Year
-61.55%
Key data
Stock price
$0.60
P/E Ratio 
0.00
DAY RANGE
$0.51 - $0.62
EPS 
-$1.80
52 WEEK RANGE
$0.51 - $1.75
52 WEEK CHANGE
-$64.51
MARKET CAP 
56.154 M
YIELD 
N/A
SHARES OUTSTANDING 
53.987 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-14-2025
BETA 
1.33
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$215,877
AVERAGE 30 VOLUME 
$142,607
Company detail
CEO: Ankit A. Mahadevia
Region: US
Website: sperotherapeutics.com
Employees: 150
IPO year: 2014
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Spero Therapeutics, Inc. focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults.

Recent news
loading